Zimmer Biomet (ZBH) PT Lowered to $101 at RBC Capital, 'Q3 Surprise Miss Puts Operational Controls in Focus'

RBC Capital analyst Shagun Singh lowered the price target on Zimmer Biomet (NYSE: ZBH) to $101.00 (from $111.00) while maintaining a Outperform rating.

The analyst comments "ZBH reported a surprise Q3 revenue miss with 5.0% y/y organic ex-fx growth vs. their guide of ~6% y/y due to multiple OUS headwinds that culminated in a single quarter. ZBH lowered its 2025 organic ex-fx revenue growth outlook by 25bps to 3.75% y/y, but maintained EPS. ZBH is not factoring in a return of the $22MM in lost Q3 sales in Q4, and expects to guide conservatively for 2026. The stock is trading down -15% as a result. Post Q3 results, we lower our PT to $101 (prior $111), but maintain our Outperform rating on valuation."

You May Also Be Interested In

• Kotak Upgrades Indusind Bank Ltd (IIB:IN) to Reduce (3)
• Tata Motors (TMCV:IN) PT Raised to INR645 at UBS
• Kotak Upgrades Torrent Pharma (TRP:IN) to Buy (1)